

## CLEANPATH PATHOGEN OVERVIEW

---

### **General Information**

Ebola disease is caused by infection with any of a group of viruses known as orthoebolaviruses (formerly ebolavirus). There are 6 types of orthoebolaviruses with 4 having caused disease in humans to date: the Ebola virus, the Sudan virus, the Taï Forest virus and the Bundibugyo virus. Ebola disease was first identified in 1976 in the Democratic Republic of Congo and Sudan. Outbreaks most often occur in sub-Saharan Africa.

### **Symptoms**

People with Ebola disease may experience "dry" symptoms early in the course of illness. These symptoms may include fever, aches, pains, and fatigue. As the person becomes sicker, the illness typically progresses to "wet" symptoms and may include diarrhea, vomiting, and unexplained bleeding. Orthoebolaviruses can cause serious and often deadly disease, with a mortality rate as high as 80 to 90 percent.

### **Transmission**

People can get Ebola disease through contact with the body fluids of an infected sick or dead person. Some people can get the disease from contact with an infected animal, like a bat or non-human primate but this is rare. Someone with Ebola disease may start getting sick 2 to 21 days after contact with an orthoebolavirus. On average, symptoms begin 8 to 10 days after exposure.

### **Prevention**

If you live in or are traveling to regions where Ebola disease has been diagnosed or is suspected, steps to protect yourself include avoiding contact with body fluids or items that may have contacted body fluids such as clothes and bedding and wearing appropriate personal protective equipment.

In the US and Canada, when an outbreak or public health emergency of international concern (PHEIC) is declared by the World Health Organization (WHO), proactive measures to protect the health and safety of the public include visitor restrictions, enhanced health screening and traveler monitoring for individuals arriving from affected areas.

For those travelling from the US and Canada to a potentially affected area, consult [Travelers' Health | CDC](#) or [Travel advice and advisories - Travel.gc.ca](#) for notices regarding your destination.

### **Vaccination**

ERVEBO® is a safe and effective vaccine approved for use by the FDA and Health Canada, but it is only effective against one of the viruses that causes Ebola disease, the Ebola virus. There are no approved vaccines for the Sudan virus, the Bundibugyo virus or the Taï Forest virus.

### **Treatment**

Two treatments are approved by the FDA to treat Ebola disease caused by the Ebola virus. The efficacy of these treatments has not been established for the Sudan virus, the Bundibugyo virus or the Taï Forest virus.

### **Cleaning and Disinfection**

Diligent and frequent cleaning and disinfection of environmental surfaces is a core strategy for the prevention and control of all infections. Ensure environmental services staff wear recommended personal protective equipment (PPE) to protect against direct skin and mucous membrane exposure to blood and body fluid contamination, and splashes or spatters that may occur during environmental cleaning and disinfection activities. Choice of PPE and appropriate donning and doffing procedures are crucial to safety when managing patients with Ebola disease. Follow specific instructions found at [CDC Viral Hemorrhagic Fevers Guidance for Personal Protective Equipment](#) or [Health Canada Infection Prevention and Control Measures for Ebola Disease in Acute Care Settings](#). Staff must also be instructed in the appropriate disposal of contaminated items/equipment.

Orthoebolaviruses are enveloped viruses, meaning they are relatively easy to inactivate with EPA or DIN registered disinfectants. In the US, refer to [EPA’s List L Registered Antimicrobial Products Effective Against Ebola Virus](#) or [Disinfectants for Emerging Viral Pathogens \(EVPs\) List Q](#) Tier 1 for enveloped viruses. In Canada, refer to [Health Canada’s Surface Disinfectants for Emerging Viral Pathogens](#).





















Diversey North American portfolio options are listed in the table below. For pathogen-specific efficacy questions, contact your disinfectant manufacturer.



Label Item	Oxivir® Express Wipes	Oxivir®1 Wipes / RTU	Oxivir® Tb Wipes / RTU	Oxivir® Three 64	Oxivir® Five 16	Virex® Plus	Virex® II 256
<b>EPA Reg</b>	Wipes - 70627-77	Wipes - 70627-77 RTU - 70627-74	Wipes - 70627-60 RTU - 70627-56	70627-82	70627-58	6836-349-70627	70627-24
<b>Technology</b>	AHP®	AHP®	AHP®	AHP®	AHP®	Quat	Quat
<b>Contact Time</b>	30 Seconds	30 Seconds	1 Minute	Three Minutes	Five Minutes	5 Minutes 1:128	10 Minutes
<b>Emerging Pathogen Language</b>	Yes, Env, Large non-env and small non-enveloped	Yes, Env, Large non-env and small non-enveloped	Yes, Env, Large non-env and small non-enveloped	Enveloped; Large & Small Non-enveloped Viruses	Enveloped; Large & Small Non-enveloped Viruses	Enveloped; Large & Small Non-enveloped Viruses	Enveloped viruses



Label Item	Alpha-HP® Multi-Surface Disinfectant Cleaner	Avert®	Wide Range® II Non-Acid Disinfectant Washroom Cleaner Concentrate	Envy® Foaming Disinfectant Cleaner
<b>EPA Reg</b>	70627-62	Wipes - 70627-75 RTU - 70627-72	6836-75-70627	70627-35
<b>Technology</b>	AHP®	Sodium Hypochlorite	Quat	Quat
<b>Contact Time</b>	5 Min	1 Min	10 Minutes	10 Minutes
<b>Emerging Pathogen Language</b>	Yes; Enveloped, Small & Large Non-enveloped viruses	Enveloped; Large & Small Non-enveloped Viruses	Enveloped; Large Non-enveloped Viruses	Enveloped Virus, Large non-enveloped Virus

<b>Product</b>	<b>Accel® 1 RTU/Wipes</b>	<b>Accel® INTERVention RTU/Wipes</b>	<b>Accel® PREvention Concentrate</b>	<b>Accel® PREvention RTU/Wipes</b>	<b>Oxivir®1 RTU / Wipes</b>	<b>Oxivir® Tb RTU / Wipes</b>
<b>Contact Time (Min)</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>3</b>	<b>30 sec</b>	<b>1</b>
						
<b>Product</b>	<b>Oxivir® Three 64</b>	<b>Oxivir® Plus (Concentrate)</b>	<b>Oxivir® Five 16 Concentrate</b>	<b>Virex® Plus</b>	<b>Crew® RR Floor &amp; Surface SC</b>	<b>Crew® RR Floor &amp; Surface NA</b>
<b>Contact Time (Min)</b>	<b>3</b>	<b>5</b>	<b>5</b>	<b>3</b>	<b>10</b>	<b>10</b>
						
<b>Product</b>	<b>CitriVir1® RTU/Wipes</b>	<b>Titan Tabs</b>	<b>Sani Stuff</b>	<b>ERADIK8 RTU</b>	<b>Wide Range II</b>	
<b>Contact Time (Min)</b>	<b>1</b>	<b>4</b>	<b>1</b>	<b>5</b>	<b>10</b>	
						

CDC: [Ebola Disease Basics | Ebola | CDC](#)

CDC: [Interim Guidance for Environmental Infection Control in Hospitals | Viral Hemorrhagic Fevers \(VHFs\) | CDC](#)

Health Canada: [Ebola disease: For health professionals, humanitarian aid workers - Canada.ca](#)

World Health Organization: [Ebola disease](#)